Marija Zdravković

Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)

Michel Marre, J. Shaw, Michael Brändle et al. · Diabetic Medicine · 2009 · 808 citations · Full text

Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

Guy De Backer, Piotr Jankowski, Kornelia Kotseva et al. · Atherosclerosis · 2019 · 350 citations · Full text

Cardiovascular Epidemiology, Cardiovascular Disease, Coronary Artery Disease +9

Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

Johan Jendle, Michael A. Nauck, David R. Matthews et al. · Diabetes Obesity and Metabolism · 2009 · 295 citations · Full text

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230))

Bernard Zinman, J. E. Gerich, John B. Buse et al. · Diabetes Care · 2010 · 291 citations

Diabetes Management, Medicine, Insulin Management +7

Delayed Care and Mortality Among Women and Men With Myocardial Infarction

Raffaele Bugiardini, Beatrice Ricci, Edina Cenko et al. · Journal of the American Heart Association · 2017 · 198 citations · Full text